Melanoma Journal Articles for February 2017
BMJ Case Reports 2017; doi:10.1136/bcr-2016-218308
CASE REPORT
Risk of cumulative toxicity after complete melanoma response with pembrolizumab
Amy Hsin-Chieh Hsieh1, Sarah Faithfull2, Michael P Brown1
- Accepted 20 January 2017
- Published 1 February 2017
A Melanoma Lymph Node Metastasis with a Donor-Patient Hybrid Genome following Bone Marrow Transplantation: A Second Case of Leucocyte-Tumor Cell Hybridization in Cancer Metastasis
Greggory S. LaBerge , Eric Duvall, Zachary Grasmick, Kay Haedicke, John Pawelek
- Published: February 1, 2017
- http://dx.doi.org/10.1371/journal.pone.0168581
Ophthalmic Images
February 9, 2017
Regression of Iris Metastasis After Systemic Treatment With Melanoma-Targeted Therapy
Cristina Fonseca, MD, MSc1; Júlia Fernandes, MD1; Rui Proença, MD, PhD1
Author Affiliations
JAMA Ophthalmol. 2017;135(2):e165462. doi:10.1001/jamaophthalmol.2016.5462
AIM2 absent in melanoma 2 [ Mandrillus leucophaeus (drill) ]
Gene ID: 105538735, updated on 8-Feb-2017
https://www.ncbi.nlm.nih.gov/gene/105538735
Comprehensive measurement of UVB-induced non-melanoma skin cancer burden in mice using photographic images as a substitute for the caliper method
Marc Bazin, Nupur K. Purohit, Girish M. Shah
Published: February 10, 2017
http://dx.doi.org/10.1371/journal.pone.0171875
Dove Press
First-line treatment of metastatic melanoma: role of nivolumab
Authors Force J, Salama AK
Received 13 April 2016
Accepted for publication 27 July 2016
Published 13 February 2017 Volume 2017:6 Pages 1—10
DOI https://doi.org/10.2147/ITT.S110479
Clinical Cancer Research
Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: a Phase 1 Clinical Trial
Mark A Exley, Philip Friedlander, Nadia Alatrakchi, Lianne Vriend, Simon C Yue, Tetsuro Sasada, Wanyong Zang, Yo Mizukami, Justice Clark, David Nemer, Ken LeClair,Christine Canning, Heather Daley, Glenn Dranoff, Anita Giobbie-Hurder, F. Stephen Hodi, Jerome Ritz and Steven P. Balk
DOI: 10.1158/1078-0432.CCR-16-0600 Published 13 February 2017
Oncology Letters
Zerumbone inhibits melanoma cell proliferation and migration by altering mitochondrial functions
Authors: Hua Yan, Ming?Yuan Ren, Zheng?Xiang Wang, Shi?Jun Feng, Si Li, Yi Cheng, Cai?Xia Hu, Shun?Qiang Gao, Guo?Qiang Zhang
Published online on: Tuesday, February 14, 2017
DOI: 10.3892/ol.2017.5742
© 2017
Melanoma Development
Molecular Biology, Genetics and Clinical Application
Editors: Bosserhoff, Anja (Ed.)
- ISBN 978-3-319-41319-8
Cancer Biology & Therapy
Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone
Kristian M. Koller, Heath B. Mackley, Jason Liu, Henry Wagner, Giampaolo Talamo, Todd D. Schell, show all
Pages 36-42 | Received 10 Oct 2016, Accepted 20 Nov 2016, Accepted author version posted online: 01 Dec 2016, Published online: 01 Dec 2016
http://dx.doi.org/10.1080/15384047.2016.126454
Journal of Cancer Science & Therapy
Received date: November 16, 2016; Accepted date: January 25, 2017; Published date: January 27, 2017
Citation: Frankel AE, Frenkel EP (2017) Melanoma Metamorphoses:Advances in Biology and Therapy. J Cancer Sci Ther 9: 325-335. doi:10.4172/1948-5956.1000437
BioRixv
Stochastic model of contact inhibition and the proliferation of melanoma in situ
Mauro Cesar C Morais, Izabella Stuhl, Alan U Sabino, Willian W Lautenschlager, Alexandre S Queiroga,Tharcisio C Tortelli, Roger Chammas, Yuri Suhov, Alexandre F Ramos
doi: https://doi.org/10.1101/110007
Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab
Yana G. Najjar, Fei Ding, Yan Lin, Robert VanderWeele, Lisa H. Butterfield and Ahmad A. Tarhini
Journal of Translational Medicine 2017 15:39
DOI: 10.1186/s12967-017-1140-9
Received: 23 November 2016
Accepted: 4 February 2017
Published: 21 February 2017
IRE1
-XBP1 pathway promotes melanoma progression by regulating IL-6/STAT3 signaling
Cheng Chen and Xuejun Zhang
Journal of Translational Medicine 2017 15:42
DOI: 10.1186/s12967-017-1147-2
Received: 6 November 2016
Accepted: 4 February 2017
Published: 21 February 2017
Characterization of long noncoding RNA and messenger RNA signatures in melanoma tumorigenesis and metastasis
Siqi Wang, Wenliang Fan, Bing Wan, Mengqi Tu, Feng Jin, Fang Liu, Haibo Xu, Ping Han
- Published: February 22, 2017
- http://dx.doi.org/10.1371/journal.pone.0172498
Journal of Clinical Oncology
Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma
Christine G. Kohn, Simon B. Zeichner, Qiushi Chen, Alberto J. Montero, Daniel A. Goldstein, and Christopher R. Flowers
DOI: http://dx.doi.org/10.1200/JCO.2016.69.6336
American Journal of Clinical Dermatology
Next-Generation Sequencing to Guide Treatment of Advanced Melanoma
Klaus G. Griewank, Bastian Schilling
Current Opinion
First Online: 22 February 2017
DOI: 10.1007/s40257-017-0260-6
Photoacoustic imaging features of intraocular tumors: Retinoblastoma and uveal melanoma
Guan Xu, Yafang Xue, Zeynep Gürsel Özkurt, Naziha Slimani, Zizhong Hu, Xueding Wang, Kewen Xia, Teng Ma, Qifa Zhou, Hakan Demirci
- Published: February 23, 2017
- http://dx.doi.org/10.1371/journal.pone.0170752
Clinical Cancer Research
Biology of Human Tumors
Inhibition of age-related therapy resistance in melanoma by rosiglitazone-mediated induction of Klotho
Reeti Behera, Amanpreet Kaur, Marie R Webster, Suyeon Kim, Abibatou Ndoye, Curtis H Kugel, Gretchen M. Alicea, Joshua X Wang, Kanad Ghosh, Phil F Cheng, Sofia Lisanti, Katie Marchbank, Vanessa Dang, Mitchell Paul Levesque, Reinhard Dummer, Xiaowei Xu, Meenhard Heryn, Andrew E. Aplin, Alexander Roesch, M. Cecilia Caino, Dario C. Altieri and Ashani T Weeraratna
DOI: 10.1158/1078-0432.CCR-17-0201 Published 23 February 2017
Future Medicine
March 2017 ,Vol. 9, No. 3, Pages 225-228 , DOI 10.2217/imt-2016-0136
(doi:10.2217/imt-2016-0136)
Case report
A rapid response to pembrolizumab in a patient with metastatic melanoma
Juan Bayo Calero*, & Victoria Aviñó Tarazona
Cancer Immunology, Immunotherapy
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
Reinhard Dummer, Christoph Hoeller, Isabella Pezzani Gruter, Olivier Michielin
First Online: 25 February 2017
DOI: 10.1007/s00262-017-1967-1
Oncotarget
PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p
Valentina Audrito1,2,*, Sara Serra1,2,*, Aureliano Stingi1,2, Francesca Orso3, Federica Gaudino1,2, Cinzia Bologna1,2, Francesco Neri1, Giulia Garaffo3, Romina Nassini4, Gianna Baroni5, Eliana Rulli6, Daniela Massi5, Salvatore Oliviero1,7, Roberto Piva3, Daniela Taverna3, Mario Mandalà8,**, Silvia Deaglio
DOI: 10.18632/oncotarget.15213
Received: August 11, 2016 Accepted: January 06, 2017 Published: February 09, 2017